AstraZeneca (BASE:AZN) - Stock Price, News & Analysis

AZN Stock Overview

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More details

AZN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	2/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 39.2% below our estimate of its fair value

Earnings are forecast to grow 18.36% per year

Earnings grew by 10.2% over the past year

Risk Analysis

Has a high level of debt

Large one-off items impacting financial results

Unstable dividend track record

AstraZeneca PLC Competitors

Merck

NYSE:MRK

US$250.9b

Novartis

SWX:NOVN

CHF 187.3b

Roche Holding

SWX:ROG

CHF 204.3b

Sanofi

ENXTPA:SAN

€116.8b

Price History & Performance

Summary of all time highs, changes and price drops for AstraZeneca
Historical stock prices
Current Share Price	UK£36,475.00
52 Week High	UK£58,050.00
52 Week Low	UK£24,288.00
Beta	0.18
11 Month Change	-16.91%
3 Month Change	-34.63%
1 Year Change	20.56%
33 Year Change	470.19%
5 Year Change	n/a
Change since IPO	52,533.48%

Recent updates

Shareholder Returns

	AZN	AR Pharmaceuticals	AR Market
7D	1.5%	-1.3%	7.6%
1Y	20.6%	-19.3%	120.6%

Return vs Industry: AZN exceeded the AR Pharmaceuticals industry which returned -19.3% over the past year.

Return vs Market: AZN underperformed the AR Market which returned 121.8% over the past year.

Price Volatility

Is AZN's price volatile compared to industry and market?
AZN volatility
AZN Average Weekly Movement	3.9%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	5.7%
10% most volatile stocks in AR Market	7.2%
10% least volatile stocks in AR Market	4.3%

Stable Share Price: AZN has not had significant price volatility in the past 3 months compared to the AR market.

Volatility Over Time: AZN's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1992	89,900	Pascal Soriot	www.astrazeneca.com

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.

AstraZeneca PLC Fundamentals Summary

How do AstraZeneca's earnings and revenue compare to its market cap?
AZN fundamental statistics
Market cap	AR$204.32t
Earnings (TTM)	AR$6.52t
Revenue (TTM)	AR$51.42t

31.3x

P/E Ratio

4.0x

P/S Ratio

Is AZN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AZN income statement (TTM)
Revenue	US$51.21b
Cost of Revenue	US$8.91b
Gross Profit	US$42.30b
Other Expenses	US$35.80b
Earnings	US$6.50b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 06, 2025

Earnings per share (EPS)	4.19
Gross Margin	82.61%
Net Profit Margin	12.68%
Debt/Equity Ratio	74.0%

How did AZN perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

71%

Payout Ratio

AZN Stock Overview

Rewards

Risk Analysis

AstraZeneca PLC Competitors

NYSE:MRK

US$250.9b

SWX:NOVN

CHF 187.3b

SWX:ROG

CHF 204.3b

ENXTPA:SAN

€116.8b

Price History & Performance

Recent News & Updates

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Recent updates

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results

Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis

Shareholder Returns

Price Volatility

About the Company

AstraZeneca PLC Fundamentals Summary

31.3x

4.0x

Earnings & Revenue

Dividends

2.2%

71%